Primary investigator Dr. Michael Lacey & current patient Patti Eilbacher sat down with Atlanta's 11Alive to talk about the study this week.
"We are looking at a compound that works in a different way than anything that's on the market right now," Dr. Lacey said. "This medication, as opposed to just treating the symptoms, is the first real medication that's gotten this far that deals specifically with the compounds or the agents that cause the disease to progress itself, so that's very exciting for us."
For full article details, visit the 11Alive site.
For more information on the study, visit the study page.